{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:17:06Z","timestamp":1744719426416,"version":"3.37.3"},"reference-count":16,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Previous studies have demonstrated low rates of seroconversion to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with chronic lymphocytic leukemia (CLL). In this national collaboration of 11 cancer centers in the United States, we aimed to further characterize and understand vaccine-induced immune responses, including T-cell responses, and the impact of CLL therapeutics (#NCT04852822). Eligible patients were enrolled in 2 cohorts (1) at the time of initial vaccination and (2) at the time of booster vaccination. The serologic response rates (anti-S) from 210 patients in the initial vaccination cohort and 117 in the booster vaccination cohort were 56% (95% confidence interval [CI], 50-63) and 68% (95% CI, 60-77), respectively. Compared with patients not on therapy, those receiving B-cell-directed therapy were less likely to seroconvert (odds ratio [OR], 0.27; 95% CI, 0.15-0.49). Persistence of response was observed at 6 months; anti-S titers increased with the administration of booster vaccinations. In the initial vaccination cohort, positive correlations were observed between the quantitative serologic response and CD4 T-cell response for the Wuhan variant and, to a lesser degree, for the Omicron variant (Spearman P\u00a0= 0.45 Wuhan; P\u00a0= 0.25 Omicron). In the booster vaccination cohort, positive correlations were observed between serologic responses and CD4 T-cell responses for both variants (P\u00a0= 0.58 Wuhan; P\u00a0= 0.57 Omicron) and to a lesser degree for CD8 T-cell responses (P\u00a0= 0.33 Wuhan; P\u00a0= 0.22 Omicron). Although no deaths from coronavirus disease 2019 (COVID-19) have been reported after booster vaccinations, patients should use caution as newer variants emerge and escape vaccine-induced immunity. This trial was registered at www.clinicaltrials.gov as #NCT04852822.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009164","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T18:18:19Z","timestamp":1671041899000},"page":"4728-4737","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"7","author":[{"given":"Chaitra","family":"Ujjani","sequence":"first","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Spurgeon","sequence":"additional","affiliation":[{"name":"3Knight Cancer Center, Oregon Health & Science University, Portland, OR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9188-5008","authenticated-orcid":false,"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"4Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-0281","authenticated-orcid":false,"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[{"name":"5Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Broome","sequence":"additional","affiliation":[{"name":"6Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"7Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Zhu","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-5325","authenticated-orcid":false,"given":"Kerry J.","family":"Laing","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison M.","family":"Winter","sequence":"additional","affiliation":[{"name":"9Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Pongas","sequence":"additional","affiliation":[{"name":"10Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L","family":"Greninger","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Koelle","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"},{"name":"8Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"},{"name":"11Department of Global Health, University of Washington, Seattle, WA"},{"name":"12Benaroya Research Institute, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"13City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"14Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"15The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"13City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Sperling","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Tu","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Sorensen","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Launchbury","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlissa J.","family":"Burrow","sequence":"additional","affiliation":[{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genesis","family":"Quezada","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-9834","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"16MD Anderson Cancer Center, University of Texas, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"issue":"10","key":"2023091114335132500_bib1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"14","key":"2023091114335132500_bib2","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"issue":"4","key":"2023091114335132500_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"2","key":"2023091114335132500_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood.2020009966","article-title":"Vaccinations in CLL: implications for COVID-19","volume":"137","author":"Shadman","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023091114335132500_bib5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0953-6205(01)00149-2","article-title":"Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients","volume":"12","author":"van der Velden","year":"2001","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2023091114335132500_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.vaccine.2007.10.053","article-title":"Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia","volume":"26","author":"Sinisalo","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"2023091114335132500_bib7","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","article-title":"BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL","volume":"6","author":"Pleyer","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2023091114335132500_bib8","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023091114335132500_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti\u2013COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2023091114335132500_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/bloodadvances.2021006633","article-title":"Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia","volume":"6","author":"Lyski","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023091114335132500_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.18088","article-title":"The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia","volume":"197","author":"Ujjani","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2023091114335132500_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/ajcp\/aqab092","article-title":"Analytical and clinical evaluation of the semiquantitative elecsys anti-SARS-CoV-2 spike protein receptor binding domain antibody assay on the roche cobas e602 analyzer","volume":"157","author":"Chan","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2023091114335132500_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/v12050513","article-title":"Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays","volume":"12","author":"Crawford","year":"2020","journal-title":"Viruses"},{"issue":"15","key":"2023091114335132500_bib14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"2023091114335132500_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjh.18149","article-title":"Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination","volume":"197","author":"Riise","year":"2022","journal-title":"Br J Haematol"},{"key":"2023091114335132500_bib16","doi-asserted-by":"crossref","first-page":"103944","DOI":"10.1016\/j.ebiom.2022.103944","article-title":"Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies","volume":"78","author":"Tada","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4728\/2077079\/blooda_adv-2022-009164-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4728\/2077079\/blooda_adv-2022-009164-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T14:34:02Z","timestamp":1694442842000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/4728\/493716\/Diminished-humoral-and-cellular-responses-to-SARS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":16,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009164","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}